Literature DB >> 11568503

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: suiting structure to need, in a family of tissue-specific enzymes.

M R El-Maghrabi1, F Noto, N Wu, N Manes.   

Abstract

The present review addresses recent advances in research into a family of bifunctional enzymes that are responsible for the twofold task of synthesizing and hydrolyzing fructose-2,6-bisphosphate (Fru-2,6-P2), which in turn regulates the rate of glycolysis in most cells. The structure of the synthetic kinase, conjoined at its carboxyl-terminus to the phosphatase, is very highly conserved throughout evolution and differentiation, with isotypic expression arising from highly variable amino-terminal and carboxyl-terminal regulatory domains. These domains, which frequently contain protein-kinase-catalyzed phosphorylation motifs, are responsible for the widely divergent kinetics observed in various tissues and species, and for the hormonal modulation that alters intracellular levels of Fru-2,6-P2. The present review discusses recent advances in relating structure to function, and the identification of new pathways of transcriptional regulation of this important family of regulatory enzymes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568503     DOI: 10.1097/00075197-200109000-00012

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  12 in total

1.  Molecular basis of the fructose-2,6-bisphosphatase reaction of PFKFB3: transition state and the C-terminal function.

Authors:  Michael C Cavalier; Song-Gun Kim; David Neau; Yong-Hwan Lee
Journal:  Proteins       Date:  2012-01-31

2.  A fundamental trade-off in covalent switching and its circumvention by enzyme bifunctionality in glucose homeostasis.

Authors:  Tathagata Dasgupta; David H Croll; Jeremy A Owen; Matthew G Vander Heiden; Jason W Locasale; Uri Alon; Lewis C Cantley; Jeremy Gunawardena
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

3.  Gene expression profiling of mice with genetically modified muscle glycogen content.

Authors:  Gretchen E Parker; Bartholomew A Pederson; Mariko Obayashi; Jill M Schroeder; Robert A Harris; Peter J Roach
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 4.  Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux.

Authors:  Brandon C Jones; Paula R Pohlmann; Robert Clarke; Surojeet Sengupta
Journal:  Cancer Metastasis Rev       Date:  2022-04-14       Impact factor: 9.237

5.  PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer.

Authors:  Minsuh Seo; Yong-Hwan Lee
Journal:  J Mol Biol       Date:  2013-12-01       Impact factor: 5.469

6.  14-3-3s regulate fructose-2,6-bisphosphate levels by binding to PKB-phosphorylated cardiac fructose-2,6-bisphosphate kinase/phosphatase.

Authors:  Mercedes Pozuelo Rubio; Mark Peggie; Barry H C Wong; Nick Morrice; Carol MacKintosh
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

7.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.

Authors:  Renate Kessler; Franziska Bleichert; Jan-Peter Warnke; Klaus Eschrich
Journal:  J Neurooncol       Date:  2007-09-06       Impact factor: 4.130

8.  Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.

Authors:  Minsuh Seo; Jeong-Do Kim; David Neau; Inder Sehgal; Yong-Hwan Lee
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

Review 9.  Roles of PFKFB3 in cancer.

Authors:  Linlin Shi; Hongming Pan; Zhen Liu; Jiansheng Xie; Weidong Han
Journal:  Signal Transduct Target Ther       Date:  2017-11-24

10.  The PFKFB3 Inhibitor AZ67 Inhibits Angiogenesis Independently of Glycolysis Inhibition.

Authors:  Besa Emini Veseli; Pieter Van Wielendaele; Mirela Delibegovic; Wim Martinet; Guido R Y De Meyer
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.